Skip to search formSkip to main contentSkip to account menu

TG4010

National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Antineoplastic AgentsCancer VaccinesMVA-MUC1-IL2 VaccineMembrane Glycoproteins

Narrower (1)

MVA-MUC1-IL2™

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.
3034 Background: TG4010 is an immunotherapy using an attenuated and modified poxvirus (MVA) coding for MUC1 and interleukin-2. A… 
Review
2014
Review
2014
Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines
Non-small-cell lung cancer usually carries a dismal prognosis. Novel treatment approaches are clearly warranted. Immunotherapy… 
2012
2012
TG4010
TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as… 
2012
2012
TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer…
TPS7610 Background: TG4010 is an immunotherapy product based on a poxvirus (MVA) coding for the MUC1 tumor-associated antigen and… 
2011
2011
Immunotherapy: A first for first-line therapy in NSCLC
Chemotherapy is the standard of care for patients with advanced-stage non-small-cell lung cancer (NSCLC), and it is widely agreed… 
2009
2009
Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010.
3027 Background: TG4010 is a targeted immunotherapy product. It was tested in combination with first-line chemotherapy in a… 
2008
2008
Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
8023 Background: TG4010 is a recombinant Modified Virus Ankara (MVA) expressing both IL2 and the tumor-associated antigen MUC1… 
2007
2007
Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
Vaccines are well known in the context of prevention of diseases caused by infectious agents. Current research is now aimed at… 
2006
2006
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cell carcinoma (RCC).
2581 Background: MUC1 is a glycoprotein often over-expressed and underglycosylated in renal cell carcinoma (RCC) making it an… 
Review
2004
Review
2004
MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC): Interim phase II data.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)